@article{50271251296349a480d19d2aeaf500e3,
title = "Does the Progestogen Used in Combined Hormonal Contraception Affect Venous Thrombosis Risk?",
keywords = "Drospirenone, Oral contraceptive, Progestin, Progestogen, Venous thromboembolism",
author = "Leo Han and Jensen, {Jeffrey T.}",
note = "Funding Information: L. Han states no conflict of interest and has received no payment in the preparation of this article. J.T. Jensen has received payments for consulting from Agile Pharmaceuticals , Abbvie Pharmaceuticals , Bayer Healthcare , ContraMed , Evofem Inc , HRA Pharma , Merck Pharmaceuticals , Teva Pharmaceuticals , and the Population Council . He has also received research funding from Abbvie, Bayer, the Population Council, the National Institute of Health , and the Bill and Melinda Gates Foundation . These companies and organizations may have a commercial or financial interest in the results of this research and technology. These potential conflicts of interest have been reviewed and managed by the Oregon Health & Science University.",
year = "2015",
month = dec,
doi = "10.1016/j.ogc.2015.07.007",
language = "English (US)",
volume = "42",
pages = "683--698",
journal = "Obstetrics and Gynecology Clinics of North America",
issn = "0889-8545",
publisher = "W.B. Saunders Ltd",
number = "4",
}